

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

APOTEX

2. Address:

2400 N. COMMERCE PARKWAY, WESTON, FL 33326

3. Principal place of business (if different from line 2):

4. Contact Name: STEVE GIULI

Telephone: 3016544964

E-mail (optional): sgiuli@apotex.com

Senate ID #: 310973-12

House ID #:

7. Client Name: ☒ Self

TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☒

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Expenses (nearest \$20,000): 250,000.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

☒ **Method A.** Reporting amounts using LDA definitions only

☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: APOTEX Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

HR 3161, FY 2008 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations -- Office of Generic Drug Funding S 1859, FY 2008 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations -- Office of Generic Drug Funding HR 2764, Consolidated Appropriations Act of 2008 -- FDA Office of Generic Drug Funding

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GIULI, STEVE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Apotex Holdings Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.

Registrant Name: APOTEX Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

HR 1908, Patent Reform Act of 2007 S. 1145, Patent Reform Act of 2007

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GIULI, STEVE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Apotex Holdings Inc., the parent company of Apotex Corp., had direct or indirect ownership interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.

Registrant Name: APOTEX Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

Centers for Medicare and Medicaid Services Rule 2238-P concerning Medicaid prescription drug reimbursement S. 1951, Fair Medicaid Drug Payment Act HR 3700, Fair Medicaid Drug Payment Act HR 3140, Saving our Community Pharmacy Act S 2499, Medicare, Medicaid and Children's Health Care Insurance Program

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GIULI, STEVE

Covered Official Position (if applicable): N/A

Name: O'CONNOR, REILLY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Apotex Holdings Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.

Registrant Name: APOTEX Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

S. 316, the Preserve Access to Affordable Pharmaceuticals Act HR 1902, Protecting Consumer Access to Generic Drugs Act HR 1038, Access to Life Savings Medicine Act S. 623, Access to Life Savings Medicine Act S 1695, Biologics Price Competition and Innovation Act S 1088, Lower Priced Drugs Act HR 3580, FDA Amendment Act of 2007 Abbreviated New Drug Application No. 76-396 for calcitonin salmon nasal spray HR 3610, the Food and Drug Import Safety Act, Section 4, User Fees Regarding Drug Safety

17. House(s) of Congress and Federal agencies contacted:

Federal Trade Commission (FTC)
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GIULI, STEVE

Covered Official Position (if applicable): N/A

Name: O'CONNOR, REILLY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above:

Apotex Holdings Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interests in companies that develop, manufacture and/or sell generic drugs, and therefore has an interest in the issues identified in this report

Signature: ON FILE Date: Jul 18, 2008

Printed Name and Title: STEVEN GIULI, DIRECTOR OF GOVE -

Registrant Name: APOTEX Client Name: Self

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

Name: O'CONNOR, REILLY

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Jul 18, 2008

Printed Name and Title: -